147 related articles for article (PubMed ID: 22892450)
1. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
4. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
8. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
9. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
10. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
11. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
[TBL] [Abstract][Full Text] [Related]
12. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
[TBL] [Abstract][Full Text] [Related]
13. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
14. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Song W; Levy R
Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
20. Development of a Murine model to dissect the CpG-oligonucleotide-enhancement of the killing of human B Cells by rituximab.
Buhé V; Pers JO; Marianowski R; Berthou C; Youinou P; Loisel S
J Autoimmun; 2010 Mar; 34(2):136-44. PubMed ID: 19726161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
